Emergent Biosolutions EBS MCM Product sales — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's mcm product sales — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's MCM product sales — total revenues?
- Emergent Biosolutions (EBS) reported MCM product sales — total revenues of $101.8M in Q1 2026.
- How has Emergent Biosolutions's MCM product sales — total revenues changed year-over-year?
- Emergent Biosolutions's MCM product sales — total revenues decreased by 35.0% year-over-year, from $156.6M to $101.8M.
- What is the long-term trend for Emergent Biosolutions's MCM product sales — total revenues?
- Over 4 years (2021 to 2025), Emergent Biosolutions's MCM product sales — total revenues has grown at a -6.0% compound annual growth rate (CAGR), from $585.9M to $456.7M.
- What does MCM product sales — total revenues mean?
- This metric represents the total gross revenue generated from the sale of Medical Countermeasure products within a specific business segment. It reflects the company's ability to monetize specialized public health and defense-related products provided to government agencies and healthcare entities. Tracking this revenue stream is essential for assessing the segment's market demand, contract performance, and contribution to the overall corporate top-line growth.